ClinicaliQ Trial Snapshot
- NAL ER IPF Respiratory Function and Safety Study — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT07036029.
- What is being tested: Escalating doses of NAL ER (N-acetylcysteine extended-release) to evaluate its safety, tolerability, and effects on respiratory function in idiopathic pulmonary fibrosis (IPF) patients.
- Patient eligibility overview: The trial enrolls participants with diagnosed IPF who meet specific safety and respiratory function criteria, allowing assessment of the drug's effects across the target disease population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Eligibility Snapshot
- : * Diagnosis of IPF as determined by a pulmonologist based on American Thoracic Society (ATS)/ European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Asociación Latinoamericana de Tórax (ALAT) guidelines. * SpO2 ≥ 92%, taken after at least 5 minutes in a sitting position, undisturbed and non-stimulated - Saturation of Hemoglobin with Oxygen as measured by pulse oximetry. * FVC ≥ 40% of Global Lung Function Initiative (GLI) 2012 predicted values- Forced Vital Capacity, as determined by spirometry adhering to ATS/ERS guidelines.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.